Thailand called it a "major success" and a "win-win approach aimed at preserving Thailand's export base and long-term economic stability". The US trade deficit with Thailand hit $45.6 billion in 2024.

BeOne Medicines' investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, has received priority medicines (PRIME) designation.

Neuralink said patients living with paralysis due to conditions such as spinal cord injury and a nervous system disease can qualify to participate in the study.